Gary Patou is Director at Xenon Pharmaceuticals Inc. (XENE). They have made 6 open-market trades across 1 company since 2006, most recently 2026-06-05.
CIK 0001283535
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
2 open-market purchases totalling $36K since 2017, against 4 sales. Too few scored purchases to measure a record yet.
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| XENE | SELL · 10b5-1 | 2026-06-05 | 2026-06-08 | $53.14 | $70K | +2.2% | +35.2% | +15.1% |
| XENE | SELL | 2024-11-22 | 2024-11-22 | $41.09 | $318K | -0.0% | -7.9% | -4.9% |
| XENE | SELL | 2023-12-14 | 2023-12-15 | $41.05 | $624K | +11.2% | +10.0% | +4.8% |
| XENE | SELL | 2023-12-13 | 2023-12-15 | $39.89 | $1.0M | +11.2% | +10.0% | +4.8% |
| XENE | SELL | 2022-11-23 | 2022-11-28 | $34.55 | $276K | +0.5% | +4.8% | +6.5% |
| XENE | BUY | 2017-08-10 | 2017-08-14 | $2.78 | $21K | +25.0% | +24.0% | -10.6% |
| XENE | BUY | 2017-08-08 | 2017-08-10 | $3.00 | $15K | +8.8% | +10.5% | -8.8% |
| PCRX | SELL · 10b5-1 | 2014-08-07 | 2014-08-08 | $100.26 | $2.0M | -18.1% | +0.8% | +0.8% |
| PCRX | SELL · 10b5-1 | 2014-07-14 | 2014-07-15 | $86.96 | $2.6M | -18.1% | +0.8% | +0.8% |
| PCRX | SELL · 10b5-1 | 2014-05-09 | 2014-05-13 | $74.39 | $2.2M | -18.1% | +0.8% | +0.8% |
| PCRX | SELL · 10b5-1 | 2013-10-01 | 2013-10-04 | $48.92 | $978K | -18.1% | +0.8% | +0.8% |
| PCRX | SELL · 10b5-1 | 2013-07-01 | 2013-07-02 | $29.44 | $1.2M | -18.1% | +0.8% | +0.8% |
| PCRX | SELL · 10b5-1 | 2013-04-12 | 2013-04-16 | $30.00 | $300K | -18.1% | +0.8% | +0.8% |
| PCRX | SELL · 10b5-1 | 2013-04-01 | 2013-04-03 | $28.15 | $845K | -18.1% | +0.8% | +0.8% |
| OSCI | SELL · 10b5-1 | 2006-05-31 | 2006-06-02 | $1.26 | $25K | N/A | N/A | N/A |
| OSCI | SELL · 10b5-1 | 2006-05-22 | 2006-05-22 | $1.33 | $40K | N/A | N/A | N/A |
| OSCI | SELL · 10b5-1 | 2006-04-25 | 2006-04-27 | $1.73 | $87K | N/A | N/A | N/A |
| OSCI | SELL · 10b5-1 | 2006-03-30 | 2006-03-31 | $1.98 | $20K | N/A | N/A | N/A |
| OSCI | SELL · 10b5-1 | 2006-03-20 | 2006-03-22 | $2.11 | $63K | N/A | N/A | N/A |
| OSCI | SELL · 10b5-1 | 2006-03-03 | 2006-03-07 | $2.10 | $21K | N/A | N/A | N/A |
| OSCI | SELL · 10b5-1 | 2006-02-27 | 2006-03-01 | $1.93 | $19K | N/A | N/A | N/A |
| OSCI | SELL · 10b5-1 | 2006-02-10 | 2006-02-14 | $2.10 | $32K | N/A | N/A | N/A |
| OSCI | SELL · 10b5-1 | 2006-02-07 | 2006-02-09 | $2.29 | $57K | N/A | N/A | N/A |
| OSCI | SELL · 10b5-1 | 2006-01-27 | 2006-01-31 | $2.15 | $22K | N/A | N/A | N/A |
| OSCI | SELL · 10b5-1 | 2006-01-12 | 2006-01-17 | $2.50 | $25K | N/A | N/A | N/A |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.